Common Nafamostat Side Effects


The most commonly reported Nafamostat side effects (click to view or check a box to report):

Cardiac Arrest (2)
Platelet Count Decreased (2)
Disseminated Intravascular Coagulation (1)
Abdominal Wall Haemorrhage (1)
Eosinophilia (1)
Blood Lactate Dehydrogenase Increased (1)
Blood Pressure Decreased (1)
Pulmonary Haemorrhage (1)
Pyrexia (1)
Tumour Lysis Syndrome (1)
Fungal Infection (1)
Renal Disorder (1)
Toxicity To Various Agents (1)
Angina Pectoris (1)
Blood Beta-d-glucan Increased (1)
Thrombotic Microangiopathy (1)
Superinfection (1)
Renal Tubular Necrosis (1)
Respiratory Failure (1)
Hyperbilirubinaemia (1)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Nafamostat Side Effects Reported to FDA



Nafamostat Side Effect Report#8342176-X
Coronary Artery Stenosis, Kidney Transplant Rejection, Nephropathy Toxic, Angina Pectoris, Myocardial Ischaemia, Chest Pain, Renal Tubular Necrosis, Toxicity To Various Agents, Renal Disorder
This is a report of a 48-year-old male patient (weight: NA) from Japan, suffering from the following health symptoms/conditions: NA, who was treated with Nafamostat Mesilate (dosage: Unk Ukn, Unk, start time:
Dec 07, 2009), combined with:
  • Sandimmune (Unk Ukn, Unk)
  • Neoral (400 Mg, Unk)
  • Tacrolimus (Unk Ukn, Unk)
  • Steroids Nos (Unk Ukn, Unk)
  • Neoral (350 Mg, Unk)
  • Mycophenolate Mofetil (Unk Ukn, Unk)
  • Basiliximab (Unk Ukn, Unk)
  • Aspirin (Unk Ukn, Unk)
and developed a serious reaction and side effect(s): Coronary Artery Stenosis, Kidney Transplant Rejection, Nephropathy Toxic, Angina Pectoris, Myocardial Ischaemia, Chest Pain, Renal Tubular Necrosis, Toxicity To Various Agents, Renal Disorder after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Nafamostat Mesilate treatment in male patients, resulting in Coronary Artery Stenosis side effect. The patient was hospitalized.
Nafamostat Side Effect Report#8021596-7
Bradycardia, Blood Pressure Decreased, Cardiac Arrest, Melaena
This report suggests a potential Nafamostat Mesilate Bradycardia side effect(s) that can have serious consequences. A 78-year-old female patient (weight: NA) from Japan was diagnosed with the following symptoms/conditions: NA and used Nafamostat Mesilate (dosage: NA) starting
Nov 29, 2011. After starting Nafamostat Mesilate the patient began experiencing various side effects, including: Bradycardia, Blood Pressure Decreased, Cardiac Arrest, MelaenaAdditional drugs used concurrently:
  • Dopamine Hydrochloride
  • Dexamedetomidine Hydrochloride (0.3 Mcg/kg/min (0.15 - 0.35 Mcg/kg/min), Intravenous, 0.25 -0.35 Mcg/kg/m, Intravenous)
  • Dexamedetomidine Hydrochloride (0.3 Mcg/kg/min (0.15 - 0.35 Mcg/kg/min), Intravenous, 0.25 -0.35 Mcg/kg/m, Intravenous)
  • Fentanyl Citrate
  • Dobutamine Hcl
  • Propofol
Although Nafamostat Mesilate demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Bradycardia, may still occur.
Nafamostat Side Effect Report#7910136-6
Disseminated Intravascular Coagulation, Blood Lactate Dehydrogenase Increased, Bone Pain, Cardiac Arrest, Tumour Lysis Syndrome, Maternal Exposure During Pregnancy, Hyperkalaemia, Respiratory Failure, Pulmonary Haemorrhage
This Disseminated Intravascular Coagulation problem was reported by a health professional from Japan. A 35-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On NS this consumer started treatment with Nafamostat Mesilate (dosage: NA). The following drugs were being taken at the same time:
  • Morphine
  • Allopurinol (300 Mg, Unk)
When using Nafamostat Mesilate, the patient experienced the following unwanted symptoms/side effects: Disseminated Intravascular Coagulation, Blood Lactate Dehydrogenase Increased, Bone Pain, Cardiac Arrest, Tumour Lysis Syndrome, Maternal Exposure During Pregnancy, Hyperkalaemia, Respiratory Failure, Pulmonary HaemorrhageThe patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Disseminated Intravascular Coagulation, may become evident only after a product is in use by the general population.
Nafamostat Side Effect Report#7309364-2
Platelet Count Decreased, Liver Disorder, Thrombotic Microangiopathy, Hyperbilirubinaemia, Abdominal Wall Haemorrhage
This Platelet Count Decreased side effect was reported by a health professional from Japan. A 50-year-old female patient (weight:NA) experienced the following symptoms/conditions: NA.The patient was prescribed Nafamostat Mesilate (drug dosage: NA), which was initiated on NS. Concurrently used drugs:
  • Tacrolimus
  • Simulect
  • Rituximab (500 Mg/ Body)
  • Prostaglandin E2
  • Ciclosporin
  • Cellcept
.After starting to take Nafamostat Mesilate the consumer reported adverse symptoms, such as: Platelet Count Decreased, Liver Disorder, Thrombotic Microangiopathy, Hyperbilirubinaemia, Abdominal Wall HaemorrhageThese side effects may potentially be related to Nafamostat Mesilate.
Nafamostat Side Effect Report#6390647-8
White Blood Cell Count Increased
This is a report of a 74-year-old female patient (weight: NA) from Japan, suffering from the following health symptoms/conditions: NA, who was treated with Nafamostat Mesilate (dosage: Unk, start time:
Sep 03, 2009), combined with:
  • Wystal (Unk)
  • Myslee
and developed a serious reaction and side effect(s): White Blood Cell Count Increased after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Nafamostat Mesilate treatment in female patients, resulting in White Blood Cell Count Increased side effect. The patient was hospitalized.
Nafamostat Side Effect Report#4572452-8
Blood Beta-d-glucan Increased, Eosinophilia, Fungal Infection, Platelet Count Decreased, Pyrexia, Superinfection
This report suggests a potential Nafamostat Blood Beta-d-glucan Increased side effect(s) that can have serious consequences. A 36-year-old male patient (weight: NA) from was diagnosed with the following symptoms/conditions: pancreatitis,fungal infection,pancreatitis chronic and used Nafamostat (dosage: 200 Mg/day) starting
Oct 25, 2004. After starting Nafamostat the patient began experiencing various side effects, including: Blood Beta-d-glucan Increased, Eosinophilia, Fungal Infection, Platelet Count Decreased, Pyrexia, SuperinfectionAdditional drugs used concurrently:
  • Prodif (8 Df/day)
  • Sandostatin (150 Ug/d)
  • Sandostatin (300 Ug/day)
  • Sandostatin (150 Ug/day)
  • Reminaron (200 Mg/day)
  • Miraclid (300 Kiu/day)
  • Tienam (2 G/day)
  • Pentcillin (4 G/day)
Although Nafamostat demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Blood Beta-d-glucan Increased, may still occur.



The appearance of Nafamostat on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.

What are common Nafamostat Side Effects for Women?

Women Side Effects Reports
Cardiac Arrest 2
Abdominal Wall Haemorrhage 1
Blood Lactate Dehydrogenase Increased 1
Blood Pressure Decreased 1
Bone Pain 1
Bradycardia 1
Disseminated Intravascular Coagulation 1
Hyperbilirubinaemia 1
Hyperkalaemia 1
Liver Disorder 1

What are common Nafamostat Side Effects for Men?

Men Side Effects Reports
Angina Pectoris 1
Blood Beta-d-glucan Increased 1
Chest Pain 1
Coronary Artery Stenosis 1
Eosinophilia 1
Fungal Infection 1
Kidney Transplant Rejection 1
Myocardial Ischaemia 1
Nephropathy Toxic 1
Platelet Count Decreased 1

Track Your Side Effects

Note Your Observations

It is really important to keep track of your health symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

    Nafamostat reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
    FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.

    Discuss Nafamostat Side Effects

    Did You Have a Nafamostat Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Nafamostat for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Nafamostat Safety Alerts, Active Ingredients, Usage Information

    More About Nafamostat

    Side Effects reported to FDA: 6

    Nafamostat safety alerts: No

    Reported deaths: 1

    Reported hospitalizations: 3

    Latest Nafamostat clinical trials

    Nafamostat Reviews

    No reviews, be a first to report a side effect via side effect reporting form

    Popular Pages